What is the point of biosimilars and the promise of lower prices if the only beneficiary is the government's economic interest? Oh wait. The government's economic interest is the only consideration in Australia's HTA system.
A good idea that will need to overcome an institutional mindset
February 19, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Moderna taps Salesforce to unify global commercial operations
April 30, 2026 - - Latest News -
How do we know the HTA institution loves patients? Because they use a love heart emoji
April 30, 2026 - - Latest News -
Australian company secures capital raise to advance amsulostat trials and strengthen pipeline
April 29, 2026 - - Latest News -
Australia urged to strengthen sunscreen literacy and label clarity
April 29, 2026 - -
'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'
April 29, 2026 - - Latest News -
We need to say it again, just in case, that this advice is about ministerial choices and not conditions
April 29, 2026 - - Latest News -
Families welcome cancer drug progress but remain cautious over timely access
April 28, 2026 - - Latest News
